| [1] |
Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China [J]. Lancet Diabetes Endocrinol, 2021, 9(6): 373-392.
|
| [2] |
Dinh Cat AN, Friederich-Persson M, White A, et al. aldosterone and obesity-related hypertension [J]. J Mol Endocrinol, 2016, 57(1): 7-21.
|
| [3] |
Vecchiola A, Lagos CF, Carvajal CA, et al. Aldosterone Production and Signaling Dysregulation in Obesity [J]. Curr Hypertens Rep, 2016, 18(3): 20.
|
| [4] |
李丽君, 侯小玲, 耿晓雯，等. 不同性别青年肥胖高血压患者醛固酮水平的变化 [J]. 中华高血压杂志, 2018, 26(01): 56-60.
|
| [5] |
Gorini S, Marzolla V, Mammi C, et al. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease [J]. Biomolecules, 2018, 8(3): 96.
|
| [6] |
Yuan Y, Xu X, Zhao C, et al. The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury [J]. Lab Invest, 2015, 95(12): 1374-1386.
|
| [7] |
Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline [J]. J Clin Endocrinol Metab, 2016, 101(5): 1889-1916.
|
| [8] |
Zhang Z, Luo Q, Tuersun T, et al. Higher prevalence of metabolic disorders in patients with bilateral primary aldosteronism than unilateral primary aldosteronism [J]. Clin Endocrinol (Oxf), 2021, 94(1): 3-11.
|
| [9] |
Zennaro MC, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism [J]. Nat Rev Endocrinol, 2020, 16(10): 578-589.
|
| [10] |
Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis [J]. Circulation, 2015, 132(22): 2134-2145.
|
| [11] |
Janowska JD. C1q/TNF-related Protein 1, a Multifunctional Adipokine: An Overview of Current Data [J]. Am J Med Sci, 2020, 360(3): 222-228.
|
| [12] |
Infante M, Armani A, Marzolla V, et al. Adipocyte Mineralocorticoid Receptor [J]. Vitam Horm, 2019, 109: 189-209.
|
| [13] |
Kargi AY, Iacobellis G. Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications [J]. Int J Endocrinol, 2014, 2014: 614074.
|
| [14] |
Cannavo A, Bencivenga L, Liccardo D, et al. Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology [J]. Oxid Med Cell Longev, 2018, 2018: 1204598.
|
| [15] |
Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway [J]. Int J Obes (Lond), 2007, 31(5): 864-870.
|
| [16] |
Friedman J. 20 years of leptin: leptin at 20: an overview [J]. J Endocrinol, 2014, 223(1): T1-8.
|
| [17] |
Faulkner JL, Bruder-Nascimento T, Belin de Chantemèle EJ. The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease [J]. Curr Opin Nephrol Hypertens, 2018, 27(2): 63-69.
|
| [18] |
Huby AC, Otvos L Jr, Belin de Chantemèle EJ. Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice [J]. Hypertension, 2016, 67(5): 1020-1028.
|
| [19] |
Nigro E, Scudiero O, Monaco ML, et al. New insight into adiponectin role in obesity and obesity-related diseases [J]. Biomed Res Int, 2014, 2014: 658913.
|
| [20] |
Shih PH, Shiue SJ, Chen CN, et al. Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis [J]. Mar Drugs, 2021, 19(3): 148.
|
| [21] |
刘华玲, 章小英, 叶建平. 肥胖相关脂肪因子与高血压的关系 [J]. 中华高血压杂志, 2019, 27(01): 25-29.
|
| [22] |
Wang Y, Li H, Yu XH, et al. CTRP1: A novel player in cardiovascular and metabolic diseases [J]. Cytokine, 2023, 164: 156162.
|
| [23] |
Xin Y, Lyu X, Wang C, Fu Y, Zhang S, Tian C, Li Q, Zhang D et al. Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients [J]. Endocr J, 2014, 61(9): 841-847.
|
| [24] |
Ren M, Pan J, Yu X, et al. CTRP1 prevents high fat diet-induced obesity and improves glucose homeostasis in obese and STZ-induced diabetic mice [J]. J Transl Med, 2022, 20(1): 449.
|
| [25] |
Han CY, Kang I, Harten IA, et al. Adipocyte-Derived Versican and Macrophage-Derived Biglycan Control Adipose Tissue Inflammation in Obesity [J]. Cell Rep, 2020, 31(13): 107818.
|
| [26] |
Reincke M, Bancos I, Mulatero P, et al. Diagnosis and treatment of primary aldosteronism [J]. Lancet Diabetes Endocrinol, 2021, 9(12): 876-892.
|
| [27] |
McCurley A, Pires PW, Bender SB, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors [J]. Nat Med, 2012, 18(9): 1429-1433.
|
| [28] |
Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction [J]. Hypertension, 2012, 59(5): 1069-1078.
|
| [29] |
Urbanet R, Nguyen Dinh Cat A, Feraco A, et al. Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase [J]. Hypertension, 2015, 66(1): 149-157.
|
| [30] |
Hirata A, Maeda N, Nakatsuji H, et al. Contribution of glucocorticoid- mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction [J]. Biochem Biophys Res Commun, 2012, 419(2): 182-187.
|
| [31] |
Frigolet ME, Gutiérrez-Aguilar R. The colors of adipose tissue [J]. Gac Med Mex, 2020, 156(2): 142-149.
|
| [32] |
Marzolla V, Feraco A, Limana F, et al. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists [J]. J Endocrinol Invest, 2022, 45(1): 215-220.
|
| [33] |
Viengchareun S, Penfornis P, Zennaro MC, et al. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes [J]. Am J Physiol Endocrinol Metab, 2001, 280(4): E640-649.
|
| [34] |
Thuzar M, Law WP, Dimeski G, et al. Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study [J]. Diabetes Obes Metab, 2019, 21(3): 509-516.
|
| [35] |
Fu M, Sun T, Bookout AL, et al. A Nuclear Receptor Atlas: 3T3-L1 adipogenesis [J]. Mol Endocrinol, 2005, 19(10): 2437-2450.
|
| [36] |
Williams JS. Evolving research in nongenomic actions of aldosterone [J]. Curr Opin Endocrinol Diabetes Obes, 2013, 20(3): 198-203.
|
| [37] |
Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets [J]. Mol Cell Endocrinol, 2012, 350(2): 223-234.
|
| [38] |
Mihailidou AS, Tzakos AG, Ashton AW. Non-Genomic Effects of Aldosterone [J]. Vitam Horm, 2019, 109: 133-149.
|
| [39] |
Gorini S, Marzolla V, Mammi C, et al. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease [J]. Biomolecules, 2018, 8(3): 96.
|
| [40] |
Bełtowski J. Salt Intake, Aldosterone Secretion, and Obesity: Role in the Pathogenesis of Resistant Hypertension [J]. Am J Hypertens, 2021, 34(6): 588-590.
|
| [41] |
Engeli S, Böhnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system [J]. Hypertension, 2005, 45(3): 356-362.
|
| [42] |
Rossi GP, Belfiore A, Bernini G, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients [J]. J Clin Endocrinol Metab, 2008, 93(7): 2566-2571.
|
| [43] |
Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice [J]. J Am Coll Cardiol, 2017, 69(14): 1811-1820.
|
| [44] |
Chao CT, Wu VC, Kuo CC, et al. Diagnosis and management of primary aldosteronism: an updated review [J]. Ann Med, 2013, 45(4): 375-383.
|
| [45] |
Bu X, Sun F, Zhang H, et al. Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome [J]. J Diabetes Res, 2022, 2022: 8932133.
|
| [46] |
Rochlani Y, Pothineni NV, Kovelamudi S, et al. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds [J]. Ther Adv Cardiovasc Dis, 2017, 11(8): 215-225.
|
| [47] |
张瑜, 王梦卉, 姚晓光, 等. 肥胖与非肥胖原发性醛固酮增多症患者的临床特点 [J]. 中华高血压杂志, 2015, 23(06): 571-573.
|
| [48] |
Zhang M, Hu T, Zhang S, et al. Associations of Different Adipose Tissue Depots with Insulin Resistance: A Systematic Review and Meta-analysis of Observational Studies [J]. Sci Rep, 2015, 5: 18495.
|
| [49] |
Chen S, Ma D, Su D, et al. The Optimal Axial Anatomical Site for a Single-Slice Area to Quantify the Total Volume of Visceral Adipose Tissue in Quantitative CT [J]. Front Endocrinol (Lausanne), 2022, 13: 870552.
|
| [50] |
Shibayama Y, Wada N, Baba S, et al. Relationship Between Visceral Fat and Plasma Aldosterone Concentration in Patients With Primary Aldosteronism [J]. J Endocr Soc, 2018, 2(11): 1236-1245.
|
| [51] |
Chen KM, Lee BC, Chen PT, et al. Evaluation of Abdominal Computed Tomography Scans for Differentiating the Discrepancies in Abdominal Adipose Tissue Between Two Major Subtypes of Primary Aldosteronism [J]. Front Endocrinol (Lausanne), 2021, 12: 647184.
|
| [52] |
Wu C, Zhang H, Zhang J, et al. Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma [J]. Endocrinology, 2018, 159(1): 227-237.
|
| [53] |
Dankel SN, Svärd J, Matthä S, et al. COL6A3 expression in adipocytes associates with insulin resistance and depends on PPARγ and adipocyte size [J]. Obesity (Silver Spring), 2014, 22(8): 1807-1813.
|
| [54] |
Lenzini L, Rossitto G, Maiolino G, et al. A Meta-Analysis of Somatic KCNJ5 K(+) Channel Mutations In 1636 Patients With an Aldosterone-Producing Adenoma [J]. J Clin Endocrinol Metab, 2015, 100(8): E1089-1095.
|
| [55] |
Zhang C, Wu L, Jiang L, et al. KCNJ5 Mutation Contributes to Complete Clinical Success in Aldosterone-Producing Adenoma: A Study From a Single Center [J]. Endocr Pract, 2021, 27(7): 736-742.
|
| [56] |
Chen KM, Chang YL, Wu TH, et al. Aldosterone-producing adenoma-harbouring KCNJ5 mutations is associated with lower prevalence of metabolic disorders and abdominal obesity [J]. J Hypertens, 2021, 39(12): 2353-2360.
|
| [57] |
van Rossum EF. Obesity and cortisol: New perspectives on an old theme [J]. Obesity (Silver Spring), 2017, 25(3): 500-501.
|
| [58] |
Er LK, Lin MC, Tsai YC, et al. Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma [J]. BMJ Open Diabetes Res Care, 2020, 8(1): e001153.
|
| [59] |
Huang CY, Huang HL, Yang KC, et al. Serum Triglyceride Levels Independently Contribute to the Estimation of Visceral Fat Amount Among Nondiabetic Obese Adults [J]. Medicine (Baltimore), 2015, 94(23): e965.
|